KINE 801
Alternative Names: KINE-801Latest Information Update: 14 Oct 2024
Price :
$50 *
At a glance
- Originator Kine Sciences
- Class Anti-inflammatories; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 14 Oct 2024 Discontinued - Preclinical for Systemic lupus erythematosus in South Korea (unspecified route) (Kine Sciences pipeline, October 2024)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in South Korea
- 12 May 2020 Preclinical trials in Systemic lupus erythematosus in South Korea (unspecified route), prior to May 2020 (Kine Sciences pipeline, May 2020)